The present review and critical appraisal of ten studies investigating irisin as a neuroprotective agent in Parkinson’s disease reveals a field characterized by intriguing mechanistic evidence combined with substantial methodological heterogeneity, unresolved paradoxes, and critical gaps limiting clinical translation. Here, FNDC5 is linked to Parkinson disease.